2. Academic Validation
  3. Breaking barriers to novel analgesic drug development

Breaking barriers to novel analgesic drug development

  • Nat Rev Drug Discov. 2017 Aug;16(8):545-564. doi: 10.1038/nrd.2017.87.
Ajay S Yekkirala 1 2 3,  David P Roberson 1 2 3,  Bruce P Bean 1,  Clifford J Woolf 1 2
Affiliations

Affiliations

  • 1 Department of Neurobiology, Harvard Medical School, Boston Children's Hospital, 300 Longwood Avenue, Boston, Massachusetts 02115, USA.
  • 2 FM Kirby Neurobiology Center Boston Children's Hospital, 300 Longwood Avenue, Boston, Massachusetts 02115, USA.
  • 3 Blue Therapeutics, Harvard Innovation Launch Lab, 114 Western Avenue, Allston, Massachusetts 02134, USA.
PMID: 28596533 DOI: 10.1038/nrd.2017.87
Abstract

Acute and chronic pain complaints, although common, are generally poorly served by existing therapies. This unmet clinical need reflects a failure to develop novel classes of analgesics with superior efficacy, diminished adverse effects and a lower abuse liability than those currently available. Reasons for this include the heterogeneity of clinical pain conditions, the complexity and diversity of underlying pathophysiological mechanisms, and the unreliability of some preclinical pain models. However, recent advances in our understanding of the neurobiology of pain are beginning to offer opportunities for developing novel therapeutic strategies and revisiting existing targets, including modulating ion channels, Enzymes and G-protein-coupled receptors.

Figures
Products